Bassel Ibrahim, MD
Interventional Cardiology · Pembroke Pines, FLNPI 1104863364
Payments from drug & device makers
Across 50 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$361
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$343
- Boston Scientific$210
- Medtronic$55
- Cardiovascular Systems Inc.$43
- Philips North America LLC$38
- plus $142 from 6 others
What the payments were for
- Food & beverage$1,192100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $361 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $343 |
| Boston Scientific | 4 | $210 |
| Medtronic | 1 | $55 |
| Cardiovascular Systems Inc. | 1 | $43 |
| Philips North America LLC | 1 | $38 |
| Cardiva Medical, Inc. | 1 | $38 |
| Heartflow, Inc. | 2 | $32 |
| Vifor Pharma, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $21 |
| Shockwave Medical, Inc | 1 | $17 |
| Acist Medical Systems, Inc. | 1 | $11 |
How this compares
$1,192 in reported general payments places this provider in the 10th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $21,621 |
| EntrestoSacubitril/Valsartan | 11 | $20,954 |
| OzempicSemaglutide | 20 | $18,742 |
| FarxigaDapagliflozin Propanediol | 12 | $17,275 |
| XareltoRivaroxaban | 13 | $15,442 |
| Praluent PenAlirocumab | 28 | $15,055 |
| BrilintaTicagrelor | 11 | $11,134 |
| Repatha SureclickEvolocumab | 12 | $6,755 |
| Ezetimibe | 106 | $2,329 |
| ClopidogrelClopidogrel Bisulfate | 164 | $1,737 |
| Rosuvastatin Calcium | 93 | $1,252 |
| Valsartan | 53 | $1,205 |
| Atorvastatin Calcium | 155 | $1,120 |
| Nebivolol Hcl | 11 | $736 |
| Metoprolol Succinate | 58 | $657 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Pembroke Pines
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.